Intergalactic Therapeutics, an Apple Tree Partners (ATP) company, is transforming medicine through non-viral gene therapy. Its proprietary integrated platform comprises three core pillars: versatile C 3DNA technology (covalently closed and circular DNA); groundbreaking precise and tunable approaches to local therapeutic delivery using the COMET electro-transfer system; and a rapid, scalable, and cost-effective manufacturing process to make gene therapy safer and more accessible. With a diversified portfolio of potential new treatments for eye diseases and beyond, Intergalactic is dedicated to helping patients around the world by bringing non-viral gene therapies into reality.